Spouting Rock Asset Management’s Blueprint Medicines BPMC Stock Holding History

Spouting Rock Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,643	Closed	-$283K	–	126
2023 Q3	$283K	Buy	5,643 +455	+9%	+$24.3K	0.09%	118
2023 Q2	$328K	Buy	5,188 +530	+11%	+$28.8K	0.12%	113
2023 Q1	$210K	Buy	+4,658	New	+$210K	0.07%	154
2022 Q4	–	Sell	-4,024	Closed	-$265K	–	144
2022 Q3	$265K	Buy	+4,024	New	+$258K	0.2%	112
2021 Q3	–	Sell	-3,833	Closed	-$337K	–	114
2021 Q2	$337K	Buy	3,833 +435	+13%	+$39.9K	0.1%	167
2021 Q1	$330K	Buy	+3,398	New	+$339K	0.1%	167

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Spouting Rock Asset Management's BPMC Position: Q4 2023 in Review

Spouting Rock Asset Management sold out of Blueprint Medicines (BPMC) in Q4 2023, closing a stake of 5,643 shares — an estimated $283K sold.

Spouting Rock Asset Management first reported a position in BPMC in Q1 2021 and held it in 6 quarters. The position peaked at $337K in Q2 2021. 259 funds tracked by Wall St. Rank hold BPMC as of Q4 2023.

Spouting Rock Asset Management reported no remaining Blueprint Medicines position as of Q4 2023 after selling out during the quarter.
Spouting Rock Asset Management sold 5,643 Blueprint Medicines shares in Q4 2023, an estimated $283K.
Spouting Rock Asset Management first reported a position in Blueprint Medicines in Q1 2021 and held it in 6 quarters.
Spouting Rock Asset Management's Blueprint Medicines position peaked at $337K in Q2 2021.
259 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2023.

Based on Spouting Rock Asset Management's 13F filing for Q4 2023, filed 16 Feb 2024.